I've just finished reading The Technological Republic (which is going to be the 1st book I read for the 2nd time after less than a week... it's that important!), and along comes this article to reinforce many of the same points. What Karp and Zamiska diagnose is not just a problem of technology, but of purpose. And what Joe proposes is not just a fix, but a spark. Together, they point to a model where America builds not just for the market, but for the republic. It’s time biotech and FDA did the same.
Good for you, Joe! And thank you. Let's get stem cells here fast. I'm 73 and suffer from football injuries like millions of others. Best & cheers, Sean
Hi Joe. I left my 30 year career in healthcare VC in Palo Alto to be part of FDA leadership at the outbreak of Covid in 2020. I resigned earlier this year, and I think some of my experience might be helpful to keep you from optimizing the wrong variables, which is where many outsiders before you have gone wrong and as a result changed or improved nothing. Ping me on LinkedIn if you are interested. -Doug Kelly
Joe, it’s exciting to hear about the potential work of the abundance institue. In Zero to One, Peter compares biotechs to software start ups and points out a lot of the risks you mentioned such as cost and regulation. One company that should be considered by the abundance institute for fast tracking is ImmunityBio. Peter speaks highly of the founder Patrick Soon-Shiong for his breakthrough cancer treatment work. Let’s make America heathy again! Thanks, Chase
The fda is in desperate need reform modernization and optimization. I started reading on molecular biology in 2015 when I volunteered to help raise money for David Baker at the Institute for Protein Design at the University of Washington. I have invested in five biotechnology startups since 2015. One of them failed fast after it was unable to secure emergency use authorization from the FDA for a rapid covid test. One of them is based on research published in 2008, and still has not secured FDA approval and may never. A chemistry professor at Northwestern University recently told me that only one in every 103 biotech startups succeed. A reflection on the difficulty of biological research and the challenges of raising money given very long FDA approval timelines today.
I've just finished reading The Technological Republic (which is going to be the 1st book I read for the 2nd time after less than a week... it's that important!), and along comes this article to reinforce many of the same points. What Karp and Zamiska diagnose is not just a problem of technology, but of purpose. And what Joe proposes is not just a fix, but a spark. Together, they point to a model where America builds not just for the market, but for the republic. It’s time biotech and FDA did the same.
Good for you, Joe! And thank you. Let's get stem cells here fast. I'm 73 and suffer from football injuries like millions of others. Best & cheers, Sean
Hi Joe. I left my 30 year career in healthcare VC in Palo Alto to be part of FDA leadership at the outbreak of Covid in 2020. I resigned earlier this year, and I think some of my experience might be helpful to keep you from optimizing the wrong variables, which is where many outsiders before you have gone wrong and as a result changed or improved nothing. Ping me on LinkedIn if you are interested. -Doug Kelly
Keep up the effort. It's obviously needed and deeply appreciated.
Joe, it’s exciting to hear about the potential work of the abundance institue. In Zero to One, Peter compares biotechs to software start ups and points out a lot of the risks you mentioned such as cost and regulation. One company that should be considered by the abundance institute for fast tracking is ImmunityBio. Peter speaks highly of the founder Patrick Soon-Shiong for his breakthrough cancer treatment work. Let’s make America heathy again! Thanks, Chase
Joe, Totally agreed!! 💯
The FDA is in serious need of reform on multiple levels as you called out.
We have a new medical device that is a true breakthrough for continuous vital signs monitoring that we have had issues going through clearances.
We received our first last year which was amazing and now are working on our second or third.
We are Texas based in the Austin area, looking to see if you have any thoughts on who could help.
Our Sempulse Halo device is saving lives today and with new clearances could save hundreds of thousands of lives a year.
super important work that abundance institute is doing - cheers
Move fast
The fda is in desperate need reform modernization and optimization. I started reading on molecular biology in 2015 when I volunteered to help raise money for David Baker at the Institute for Protein Design at the University of Washington. I have invested in five biotechnology startups since 2015. One of them failed fast after it was unable to secure emergency use authorization from the FDA for a rapid covid test. One of them is based on research published in 2008, and still has not secured FDA approval and may never. A chemistry professor at Northwestern University recently told me that only one in every 103 biotech startups succeed. A reflection on the difficulty of biological research and the challenges of raising money given very long FDA approval timelines today.
Ben! I agree!